Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE).
Irini SeretiKathryn Shaw-SalibaLori E DoddRobin L DewarSylvain LaverdureShawn BrownOlivier Tshiani MbayaJean Jacques Muyembe TamfumPlacide Mblala-KingebeniYdrissa SowEsther AkpaMory Cherif HaidaraKarine Fouth TchosAbdoul Habib BeavoguiAaron NealDona ArlindaDewi LokidaLouis GrueMary SmolskisLaura A McNayDehkontee Gayedyu-DennisGuillermo M Ruiz-PalaciosAbelardo Montenegro-LiendoMoctar TounkaraSeydou SamakeGanbolor JargalsaikhanDelgersaikhan ZulkhuuShera WeyersTyler BonnettGail E PotterRandy StevensAdam RupertJamila AboulhabJean-Luc BiampataAlexandre DelamoBienvenu Salim CamaraHerman Kosasih IndonesiaMuhammad KaryanaJames T DuworkoJustino Regalado-PinedaPaola Del Carmen Guerra-de-BlasSeydou DoumbiaDjeneba DabitaoNaranjargal DashdorjNaranbaatar DashdorjKevin NewellAlyson FrancisKevin B RubensteinVictoria BeraIman GulatiRatna SardanaMonica MillardRenee RidzonSally HunsbergerPublished in: PloS one (2022)
In response to the COVID-19 pandemic, COVID-19 vaccines have been developed, and the World Health Oraganization (WHO) has granted emergency use listing to multiple vaccines. Studies of vaccine immunogenicity data from implementing COVID-19 vaccines by national immunization programs in single studies spanning multiple countries and continents are limited but critically needed to answer public health questions on vaccines, such as comparing immune responses to different vaccines and among different populations.